Table S1. Response evaluation (by the IRRC) in the ITT and PP sets.
| Treatment responses | IBI305 (n, %) | Bevacizumab (n, %) | ORR ratio (90% CI) |
|---|---|---|---|
| Number of patients in ITT set | 224 | 226 | |
| Objective response rate (ORR) | 98 (43.8) | 104 (46.0) | 0.95 (0.798, 1.129) |
| Complete response (CR) | 0 | 0 | |
| Partial response (PR) | 98 (43.8) | 104 (46.0) | |
| Stable disease (SD) | 102 (45.5) | 91 (40.3) | |
| Disease progression (PD) | 11 (4.9) | 15 (6.6) | |
| Unable to evaluation (NE) | 13 (5.8) | 16 (7.1) | |
| Number of patients in PP set | 216 | 217 | |
| Objective response rate (ORR) | 96 (44.4) | 100 (46.1) | 0.96 (0.807, 1.145) |
| Complete response (CR) | 0 | 0 | |
| Partial response (PR) | 96 (44.4) | 100 (46.1) | |
| Stable disease (SD) | 101 (46.8) | 90 (41.5) | |
| Disease progression (PD) | 11 (5.1) | 14 (6.5) | |
| Unable to evaluate (NE) | 8 (3.7) | 13 (6.0) |
IRRC, independent radiological review committee; ITT, intention to treat; PP, per protocol; CI, confidential interval; ORR, objective response rate.